These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 11874927

  • 1. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
    Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.
    Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L, Dicembrini I, Mannucci E.
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [Abstract] [Full Text] [Related]

  • 4. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Klonoff DC, Evans ML, Lane W, Kempe HP, Renard E, DeVries JH, Graungaard T, Hyseni A, Gondolf T, Battelino T.
    Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB, CONTROL Study Group.
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [Abstract] [Full Text] [Related]

  • 10. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
    Bode BW, Iotova V, Kovarenko M, Laffel LM, Rao PV, Deenadayalan S, Ekelund M, Larsen SF, Danne T.
    Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
    [Abstract] [Full Text] [Related]

  • 12. [Short acting insulin analogues for treating diabetic patients with CSII (continuous subcutaneous insulin infusion)].
    Jermendy G.
    Orv Hetil; 2006 Nov 19; 147(46):2223-6. PubMed ID: 17396394
    [Abstract] [Full Text] [Related]

  • 13. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.
    van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G.
    Diabetes Technol Ther; 2011 Jun 19; 13(6):607-14. PubMed ID: 21457066
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS, Dominguez-Lopez ME, Gonzalez-Molero I, Machado A, Martin V, Cardona I, de-la-Higuera M, Tapia MJ, Soriguer F, Anarte MT, Rojo-Martínez G.
    Med Clin (Barc); 2016 Mar 18; 146(6):239-46. PubMed ID: 26656958
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, Miselli V, Brandolini S, Fabbri T, Meandri P, Cannatà F.
    Diabetes Technol Ther; 2008 Dec 18; 10(6):495-8. PubMed ID: 19049379
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
    Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K.
    Diabet Med; 2017 Feb 18; 34(2):167-173. PubMed ID: 26773446
    [Abstract] [Full Text] [Related]

  • 20. Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients with Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart.
    Thrasher J, Bhargava A, Rees TM, Wang T, Guzman CB, Glass LC.
    Endocr Pract; 2015 Mar 18; 21(3):247-57. PubMed ID: 25370322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.